Skip to main content

Advertisement

SpringerLink
Log in

Chronic allograft nephropathy and mycophenolate mofetil introduction in paediatric renal recipients

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Mycophenolate mofetil (MMF) introduction with concurrent reduction in calcineurin inhibitors has been shown to be beneficial in chronic allograft nephropathy (CAN) in adults. MMF was introduced to 19 children with CAN 26.3±5.8 (range 3.1–82.6) months after transplantation. Patients were followed up for a mean of 13.2±2.9 (range 1.2–51.1) months. The mean initial MMF dose was 660±56 mg/m2 per day, increased to 1,042±73 mg/m2 per day a year later. Cyclosporin was reduced from 138±10 mg/m2 per day at MMF introduction, to 116±15 mg/m2 per day at 6 months and 107±24 mg/m2 per day at 1 year. Six months prior to MMF introduction GFR deteriorated by −32.7±7.3 ml/min per 1.73m2 per year. Six months after the introduction of MMF, GFR improved by +26.2±7.1 ml/min per 1.73m2 per year (P <0.001). The introduction of MMF significantly reduced both the graft rejection rate (P=0.01) and systolic blood pressure (P=0.01), without a significant change in antihypertensive treatment. Haematological parameters did not significantly differ before and after MMF introduction. The introduction of MMF in paediatric renal transplant recipients with CAN may cause a significant improvement in GFR in both the short-term and the long-term and may well have a beneficial effect on systolic blood pressure. MMF has the potential to enable CNI-sparing protocols to be adopted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Schweitzer EJ, Matas AJ, Gillingham KJ (1991) Causes of renal allograft loss: progress in the 1980s, challenges for the 1990s. Ann Surg 214:679–688

    PubMed  Google Scholar 

  2. Matas A, Gillingham K, Sutherland D (1993) Half-life and risk factors for kidney transplant outcome—importance of death with function. Transplantation 55:757–761

    PubMed  Google Scholar 

  3. Weir MR, Anderson L, Fink JC, Gabregiorgish K, Scweitzer EJ, Hoehn-Saric E, Klassen DK, Cangro CB, Johnson LB, Kuo PC, Lim JY, Bartlett ST (1997) A novel approach of chronic allograft nephropathy. Transplantation 64:1706–1710

    Article  PubMed  Google Scholar 

  4. European Multicentre Trial Group (1987) Cyclosporin in cadaveric renal transplantation: 5 years follow-up of a multicentre trial. Lancet 2:506–507

    PubMed  Google Scholar 

  5. Cecka J (1991) The UNOS scientific transplant registry: ten years of renal transplants. Clin Transplant 4:1–14

    Google Scholar 

  6. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM (1996) Chronic cyclosporin nephropathy in renal transplantation. Transplant Proc 28:2100

    PubMed  Google Scholar 

  7. Van Buren DH, Burke JF, Lewis RM (1994) Renal function in patients receiving long-term cyclosporin therapy. J Am Soc Nephrol 4:S17

    PubMed  Google Scholar 

  8. Allison AC, Eugui EM, Sollinger HW (1993) Mycophenolate mofetil (RS-61443): mechanisms of actions and effects in transplantation. Transplant Rev 7:129

    Google Scholar 

  9. Halloran P, Matthew T, Tomlanovich MS, Groth G, Hooftman L, Baker C (1997) Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomised, double-blind, clinical studies in prevention of rejection. Transplantation 63:39

    Article  PubMed  Google Scholar 

  10. Hauser IA, Sterzel RB (1999) Mycophenolate mofetil: therapeutic applications in kidney transplantation and immune-mediated renal disease. Curr Opin Nephrol Hypertens 8:1

    Article  PubMed  Google Scholar 

  11. Hueso M, Bover J, Seron D, Gil-Vernet S, Sabate I, Fulladosa X, Ramos R, Coll O, Alsina J, Grinyo JM (1998) Low-dose cyclosporin and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 66:1727–1731

    Article  PubMed  Google Scholar 

  12. Ducloux D, Fournier V, Bresson-Vautrin C, Rebibou J-M, Billerey C, Saint-Hillier Y, Chalopin J-M (1998) Mycophenolate mofetil in renal transplant recipients with cyclosporin-associated toxicity. Transplantation 65:1504–1506

    Article  PubMed  Google Scholar 

  13. Houde I, Isenring P, Boucher D, Noel R, Lachanche J-G (2000) Mycophenolate mofetil, an alternative to cyclosporin A for long-term immunosuppression in kidney transplantation. Transplantation 70:1251–1253

    Article  PubMed  Google Scholar 

  14. Schrama YC, Joles JA, van Tool A, Boer P, Koomans HA, Rene RJ (2000) Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporin in stable renal transplant recipients. Transplantation 69:376–383

    Article  PubMed  Google Scholar 

  15. Weir MR, Ward MT, Blahut SA, Klassen DK (2001) Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 59:1567–1573

    Article  PubMed  Google Scholar 

  16. Butani L, Palmer J, Baluarte HJ, Polinsky MS (1999) Adverse effects of mycophenolate mofetil in paediatric renal transplant recipients with presumed chronic rejection. Transplantation 68:83–86

    Article  PubMed  Google Scholar 

  17. Virji M, Carter JE, Lirenman DS (2001) Single-center experience with mycophenolate mofetil in paediatric renal transplant recipients. Pediatr Transplant 5:293–296

    Article  PubMed  Google Scholar 

  18. Jungraithmayr T, Staskewitz A, Kirste G, Boswald M, Bulla M, Burghard R, Dippell J, Greiner C, Helmchen U, Klare B, Klaus G, Leichter HE, Mihatsch MJ, Michalk DV, Misselwitz J, Plank C, Querfeld U, Weber LT, Wiesel M, Tonshoff B, Zimmerhackl LB (2003) Paediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: results after three years. Transplantation 75:454–461

    Article  PubMed  Google Scholar 

  19. Morris MC, Allanby CW, Toseland P, Haycock GB, Chandler C (1982) Evaluation of a height/plasma creatinine formula in the measurement of glomerular filtration rate. Arch Dis Child. 57:611–615

    Google Scholar 

  20. de Man SA, Andre J, Bachmann H, Grobbee DE, Ibsen KI, Laaser U, Lippert P, Hofman A (1991) Blood pressure in childhood: pooled findings of six European studies. J Hypertens 9:109–114

    PubMed  Google Scholar 

  21. O’Hair DP, McManus RP, Komorowski R (1994) Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil. Ann Thorac Surg 58:1311

    PubMed  Google Scholar 

  22. Allison AC, Kowalski WJ, Muller CD, Eugui EM (1993) Mechanisms of action of mycophenolic acid. Ann N Y Acad Sci 696:63

    Google Scholar 

  23. Allison AC, Almquist SJ, Muller CD, Eugui EM (1991) In vitro immunosuppressive effects of mycophenolic acid and as an ester prodrug, RS-61443. Transplant Proc [Suppl 2] 23:10

  24. Eugui EM, Almquist SJ, Muller CD, Allison AC (1991) Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 33:175

    PubMed  Google Scholar 

  25. Anguita A, Repetto HA, Rodriguez-Rilo L, Vazquez LA, Iturzaeta A, Morrone G, Deheza R, Maldonado L, Goldberg JL (1999) The replacement of azathioprine by mycophenolate mofetil in paediatric patients with specific risks in renal transplantation. Transplant Proc 31:2279

    Article  PubMed  Google Scholar 

  26. Ferraris JR, Tambutti ML, Redal MA, Bustos D, Ramirez JA, Prigoshin N (2000) Conversion from azathioprine to mycophenolate mofetil in paediatric renal transplant recipients with chronic rejection. Transplantation 70:297–301

    Article  PubMed  Google Scholar 

  27. David-Neto E, Araujo LMP, Lemos FC, David DSR, Mazzucchi E, Nahas WC, Arap S, Ianhez LE (2001) Introduction of mycophenolate mofetil and cyclosporin reduction in children with chronic transplant nephropathy. Pediatr Transplant 5:302–309

    Article  PubMed  Google Scholar 

  28. Filler G, Gellermann J, Zimmering M, Mai I (2000) Effect of adding mycophenolate mofetil in paediatric renal transplant recipients with chronic cyclosporine nephrotoxicity. Transpl Int 13:201–206

    Article  PubMed  Google Scholar 

  29. Henne T, Latta K, Strehlau J, Ehrich JH, Offner G (2003) Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy. Transplantation 76:1326–1330

    Article  PubMed  Google Scholar 

  30. Francois H, Durrbach A, Amor M, Djeffal R, Kriaa F Paradis V, Bedossa P, Charpentier B (2003) The long-term effect of switching from cyclosporin A to mycophenolate mofetil in chronic renal graft dysfunction compared with conventional management. Nephrol Dial Transplant 18:1909–1916

    Article  PubMed  Google Scholar 

  31. Miller LW (2002) Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2:807–818

    Article  PubMed  Google Scholar 

  32. Agamanolis DP, Tan JS, Parker DL (1979) Immunosuppressive measles encephalitis in a patient with renal transplantation. Arch Neurol 36:686–690

    PubMed  Google Scholar 

  33. Klapper PE, Cleator GM, Clarke MC, Postlethwaite RJ (1991) Measles immunization. Arch Dis Child 66:369

    Google Scholar 

  34. Kalman S, Bakkaloglu SA, Ozkaya O, Buyan N, Soylemezoglu O (2002) Measles: a rare communicable disease in a child with renal transplantation. Pediatr Transplant 6:432–434

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Paediatric Nephrology, Guy’s Hospital, St. Thomas’ Street, London, SE1 9RT, UK

    Larissa Kerecuk & Judy Taylor

  2. GKT Medical School, Guy’s Hospital, London, UK

    Godfrey Clark

Authors
  1. Larissa Kerecuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Judy Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Godfrey Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Larissa Kerecuk.

Additional information

Preliminary results of this study were presented at the 7th Annual Congress of the British Transplantation Society, 2004, Birmingham, UK, and at the 13th Congress of the Internal Pediatric Nephrology Association, 2004, Adelaide, Australia

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kerecuk, L., Taylor, J. & Clark, G. Chronic allograft nephropathy and mycophenolate mofetil introduction in paediatric renal recipients. Pediatr Nephrol 20, 1630–1635 (2005). https://doi.org/10.1007/s00467-005-2012-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-005-2012-8

Keywords

Search

Navigation